Centre Hospitalier in Lannion buys DrugLog™
Pharmacolog Sarl has received an order for a DrugLog™ system for placement at Lannion Hospital in Brittany, France. The system will be used for the final check of chemotherapy preparations at the hospital pharmacy.
Pharmacolog Sarl has received an order for a DrugLog® system which will be placed at Centre Hospitalier Lannion-Trestel in Lannion, France. The hospital belongs to the GHT Territoire d’Armor hospital group. The system will be used for the final control of chemotherapy preparations compounded at the hospital pharmacy.
Didier Dubois, Sales Manager Pharmacolog SARL comments: “I am pleased that Lannion Hospital has decided to install DrugLog™ to control their cytotoxic preparations. It has been a preasure to collaborate with Mme Trainaud, the head of pharmacy and Mr Ducluzeau the biomed engineer. From the Pharmacolog’s perspective, it is very encouraging to expend the installed base with the first system in Brittany.”
For more information contact:
Mats Högberg, CEO
Email: [email protected]
Phone: +46 70-546 50 21
About Pharmacolog AB
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
The following trademarks are owned and protected by Pharmacolog i Uppsala AB: Pharmacolog™-logo, DrugLog™, WasteLog™, PrepLog™ and Pharmacolog Dashboard™
Further information regarding the company is available at www.pharmacolog.com.
The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through [email protected]
iZafe acquires Pilloxa, carries out a directed issue of shares and warrants to qualified investors and issues warrants free of charge to existing shareholders
iZafe Group AB (publ) ("iZafe" or the "Company") has today entered into a share purchase agreement with the owners of Pilloxa AB ("Pilloxa") regarding the acquisition of all outstanding shares of Pilloxa in accordance with the letter of intent communicated by press release on...
iZafe tillträder förvärvet av Pilloxa, genomför en riktad emission av aktier och teckningsoptioner till kvalificerade investerare samt emitterar vederlagsfria teckningsoptioner till befintliga aktieägare
iZafe Group AB (publ) (”iZafe” eller ”Bolaget”) har idag ingått ett aktieöverlåtelseavtal med ägarna i Pilloxa AB (”Pilloxa”) avseende förvärvet av samtliga aktier i bolaget i enlighet med den avsiktsförklaring som kommunicerats genom pressmeddelande den 18 augusti 2022. Tillträdet till aktierna i P...
CEO Ulf Jungnelius to leave Isofol Medical on June 1, 2023
GOTHENBURG, Sweden, November 28, 2022 – Isofol Medical AB (publ) (Nasdaq Stockholm: ISOFOL), announced today that Chief Executive Officer Dr. Ulf Jungnelius M.D. and Isofol’s Board of Directors have agreed that Ulf will step down as CEO of Isofol on June 1, 2023. Isofol’s Board of Directors will tak...
Isofol Medicals vd Ulf Jungnelius slutar den 1 juni 2023
GÖTEBORG, Sverige, 28 november 2022 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL) tillkännagav idag att bolagets vd Dr Ulf Jungnelius M.D. och Isofols styrelse har kommit överens om att Ulf slutar som vd för Isofol den 1 juni 2023. Isofols styrelse kommer att ta ett beslut angående en ny vd...